Home Macusoft

Macusoft

In operation
-
Biotech Company Focused on Artificial Intelligence
Basic
Enterprise Profile

Basic Information

Without Regular Monitoring and Treatment, 237 Million People Globally Suffer from Chronic Eye Conditions Leading to Severe Vision Loss. The Aging Population and Rising Diabetes Rates Have Caused a Surge in Demand That Even the Most Advanced Healthcare Systems Cannot Handle. Consequently, Vision Loss Among Patients Is Increasing, Primarily Due to Treatment Delays.Macusoft has Developed an Artificial Intelligence (AI) Clinical Decision Support System for the Optimal Management of Preventable Vision-Threatening Eye Diseases. Tailored Treatment Plans Are Created for Each Patient and Optimized Results Are Provided On-Site in Real-Time.The AI System is Cloud-Based and Can Be Rapidly Deployed at Scale Across Entire Healthcare Systems to Alleviate the Burden on Ophthalmology and Reduce Unnecessary Vision Loss.
Macusoft
London,England,United Kingdom
unclear
--
ai@macusoft.com

Enterprise Profile

Industrial Sector
Internet Health Service Platform
Technology
Artificial Intelligence
Concept
Disease Treatment
Application Scenarios
Smart Healthcare Technical Concepts